A and immunostaining of the tissue showed that the adenoma cells were positive for GH, PRL or TSH. The patient was treated with bromocriptine at a daily oral dose of 10 mg after surgery. Serum TSH were initially suppressed but returned within reference intervals with persistent normalized free T4 levels. Serum PRL became undetectable and GH levels were stable around 6 ng/ml except the periods of poor drug compliance, when serum TSH, GH and PRL levels rose considerably. The patient was followed-up for 10 years without any change in the residual adenoma tissues as detected by magnetic resonance imaging. These findings suggest that long-term bromocriptine therapy is effective in treating the hypersecretory state of a plurihormonal adenoma secreting TSH, GH and PRL.
Abstract.
A 48-year-old female presented with acromegaly, amenorrhea and hyperthyroidism associated with high serum free T4 levels and measurable TSH concentrations. The administration of GHRH induced significant increases in GH, PRL and TSH. Conversely, intravenous infusion of dopamine or oral administration of bromocriptine effectively inhibited GH, PRL and TSH secretion. Serum a-subunit levels were neither affected by GHRH, dopamine nor bromocriptine. Transsphenoidal surgery was performed and immunostaining of the tissue showed that the adenoma cells were positive for GH, PRL or TSH. The patient was treated with bromocriptine at a daily oral dose of 10 mg after surgery. Serum TSH were initially suppressed but returned within reference intervals with persistent normalized free T4 levels. Serum PRL became undetectable and GH levels were stable around 6 ng/ml except the periods of poor drug compliance, when serum TSH, GH and PRL levels rose considerably. The patient was followed-up for 10 years without any change in the residual adenoma tissues as detected by magnetic resonance imaging. These findings suggest that long-term bromocriptine therapy is effective in treating the hypersecretory state of a plurihormonal adenoma secreting TSH, GH and PRL. TRH administration induced parallel increases in serum levels of GH (+109%; percent increase above basal value), PRL (+115%) and TSH (+103%), whereas serum a-subunit did not respond to TRH [15] . GHRH administration resulted in a marked increase in serum GH (+415% and +885%; before and after surgery), and moderate and mild increases in serum PRL (+113% and +184%; before and after surgery) and TSH (+53% and +113%; before and after surgery), respectively ( Fig. 1 Effects of GHRH administration on serum GH, PRL, TSH and a-subunit levels before (A) and after (0) surgery and during bromocriptine treatment for 5 months (•). Partial removal of the tumor resulted in moderate decreases in GH, TSH and asubunit (-68%, -26% and -56%, respectively), whereas PRL levels were essentially unchanged after surgery (Fig. 3) .
Since serum free 14, GH and PRL levels were still high and since the administration of a dopamine agonist decreased the hormonal levels, Effects of dopamine and bromocriptine on serum GH (0), PRL (•), TSH ([]) and asubunit (/) levels. Dopamine (2 µg/kg/min) was infused intravenously for 120 min, and bromocriptine (2.5 mg) was administered orally. Twenty-four hour diurnal profiles of serum GH, PRL, TSH and a-subunit before (A') and after (0) surgery and during bromocriptine treatment for 2 weeks (•).
long-term treatment with bromocriptine at a daily oral dose of 10 mg has been initiated from January 20, 1989. GHRH-induced GH secretion was unchanged during bromocriptine treatment, but PRL and TSH secretion were greatly and moderately suppressed, respectively, during treatment (Fig. 1) . Clinical symptoms such as palpitation and hand tremor subsided and excessive perspiration decreased. Basal PRL became undetectable and GH levels were stable around 6 ng/ml except the periods of poor drug compliance, when serum GH and PRL increased significantly, as shown in Fig. 4 Serial changes in serum TSH (0), free T4 (/), GH (0) and PRL (•) levels during bromocriptine treatment. Bromocriptine was administered orally at a daily dose of 10 mg. Broken lines in the box indicate the periods of poor drug compliance. 
